newsfilter
← Earnings
Earnings Releases·

Kalaris Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $11.0 million (vs. $11.9 million YoY) with total operating expenses declining to $11.8 million (vs. $12.7 million YoY), while cash and marketable securities decreased to $82.9 million from $118.0 million at year-end 2025.
  • Clinical timelines for TH103 in nAMD have shifted, with preliminary Phase 1b/2 data now expected in H2 2027 and a potential Phase 3 initiation in 2028.
  • Technology transfer to commercial-scale manufacturer KBI Biopharma was successfully completed with test batches meeting Phase 3 specifications, though a pilot batch failure has delayed clinical supply availability until Q2 2027.
  • Current cash reserves are projected to fund operations into 2028, supporting the extended development timeline resulting from manufacturing delays.
Company
KALARIS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology